Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Protalix BioTherapeutics, Inc.v234368_ex99-1.htm
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 

 
FORM 8-K
 

 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported):September 8, 2011
 

Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
 

 
         
Florida
 
001-33357
 
65-0643773
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
     
2 Snunit Street
 
20100
Science Park, POB 455
   
Carmiel, Israel
   
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code +972-4-988-9488
 
 
(Former name or former address, if changed since last report.)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 7.01.  Regulation FD Disclosure

On September 8, 2011, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that an article entitled "Pivotal Trial with Plant-Cell–Expressed Recombinant Glucocerebrosidase, taliglucerase alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease" has been published in Blood, the Journal of the American Society of Hematology.  The full article can be found on the American Society of Hematology’s website at http://bloodjournal.hematologylibrary.org. (First Edition Paper, pre-published online September 6, 2011; DOI 10.1182/blood-2011-07-366955).  A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.  Financial Statements and Exhibits

(d) 
Exhibits

99.1 
Press release dated September 8, 2011

 
2

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PROTALIX BIOTHERAPEUTICS, INC.
 
     
       
Date: September 8, 2011
By:
/s/ David Aviezer  
  Name: David Aviezer, Ph.D.  
  Title: President and  
    Chief Executive Officer  
 
 
3